Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Targeting the androgen receptor (AR) pathway prolongs survival in patients with prostate cancer, but resistance rapidly develops. Understanding this resistance is confounded by a lack of noninvasive means to assess AR activity in vivo. We report intracellular accumulation of a secreted antigen-targeted antibody (SATA) that can be used to characterize disease, guide therapy, and monitor response. AR-regulated human kallikrein-related peptidase 2 (free hK2) is a prostate tissue-specific antigen produced in prostate cancer and androgen-stimulated breast cancer cells. Fluorescent and radio conjugates of 11B6, an antibody targeting free hK2, are internalized and noninvasively report AR pathway activity in metastatic and genetically engineered models of cancer development and treatment. Uptake is mediated by a mechanism involving the neonatal Fc receptor. Humanized 11B6, which has undergone toxicological tests in nonhuman primates, has the potential to improve patient management in these cancers. Furthermore, cell-specific SATA uptake may have a broader use for molecularly guided diagnosis and therapy in other cancers.

Original publication

DOI

10.1126/scitranslmed.aaf2335

Type

Journal article

Journal

Sci Transl Med

Publication Date

30/11/2016

Volume

8

Keywords

Adenocarcinoma, Animals, Antibodies, Bone Neoplasms, Cell Line, Tumor, Histocompatibility Antigens Class I, Humans, Male, Mice, Mice, Inbred BALB C, Neoplasm Metastasis, Phenotype, Positron-Emission Tomography, Prostatic Neoplasms, Receptors, Androgen, Receptors, Fc, Tissue Kallikreins, Tomography, X-Ray Computed, Treatment Outcome